HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Callahan, R. J. Articles by Fischman, A. J. Search for Related Content PubMed PubMed Citation Articles by Callahan, R. J. Articles by Fischman, A. J.

Biodistribution and Dosimetry of Technetium-99m-Hydrazino Nicotinamide IgG: Comparison with Indium-111-DTPA-IgG

Division of Nuclear Medicine, Department of Radiology, and Clinical Investigation Unit of the Medical Service, Massachusetts General Hospital
Departments of Radiology and Medicine, Harvard Medical School, Boston, Massachusetts
Johnson Matthey Pharmaceutical Research, West Chester, Pennsylvania

Correspondence: For correspondence or reprints contact: Alan J. Fischman, MD, Division of Nuclear Medicine, Department of Radiology, Massachusetts General Hospital, 32 Fruit St., Boston, MA 02114.

ABSTRACT

The biological behavior of human polyclonal immunoglobulin G (IgG), radiolabeled with ^99mTc via a nicotinyl hydrazine derivative (^99mTc-HYNIC-IgG), was evaluated in normal human subjects. Methods: Initial biodistribution and dosimetry studies were performed in six normal male volunteers. Additionally, ^99mTc-IgG and ¹¹¹In-DTPA-IgG were co-injected into six subjects and scintillation camera images were acquired at 6 and 18 hr later and serial blood and urine samples were collected. Biodistribution of both radiopharmaceuticals were measured by region of interest analysis. In the dual-injection group, images were crossover-corrected. Results: All subjects tolerated injection of the radiolabeled IgG preparations without apparent ill effects. Biodistribution of the two antibody preparations were remarkably similar with an increase in liver and abdominal activity for the ¹¹¹In preparation. Linear correlation of the tissue-to-blood ratios of ^99mTc and ¹¹¹In-labeled IgG was observed at both times (r² > 0.98). The slopes of the regression line were 0.97 and 0.76 at 6 and 18 hr, respectively. The beta phase of the blood clearance of ^99mTc-HYNIC-IgG was significantly delayed (p < 0.01) compared with ¹¹¹In-IgG (t_1/2: 51.9 ± 6.5 versus 35.3 ± 3.4 hr). In contrast, the volumes of distribution and urinary excretions of the radiopharmaceuticals were not significantly different. Conclusion: These studies establish that the biodistribution of ^99mTc-HYNIC-IgG in normal human subjects is nearly identical to ¹¹¹In-DTPA-IgG.

Key Words: technetium-99m-HYNIC-IgG • indium-111-DTPA-IgG • dosimetry

This article has been cited by other articles:

				S. O'Mahony, C. K. Solanki, R. W. Barber, P. S. Mortimer, A. D. Purushotham, and A. M. Peters Imaging of Lymphatic Vessels in Breast Cancer-Related Lymphedema: Intradermal Versus Subcutaneous Injection of 99mTc-Immunoglobulin. Am. J. Roentgenol., May 1, 2006; 186(5): 1349 - 1355. [Abstract] [Full Text] [PDF]

				A. Goel, J. Baranowska-Kortylewicz, S. H. Hinrichs, J. Wisecarver, G. Pavlinkova, S. Augustine, D. Colcher, B. J.M. Booth, and S. K. Batra 99mTc-Labeled Divalent and Tetravalent CC49 Single-Chain Fv's: Novel Imaging Agents for Rapid In Vivo Localization of Human Colon Carcinoma J. Nucl. Med., October 1, 2001; 42(10): 1519 - 1527. [Abstract] [Full Text] [PDF]